BioMarin Announces Public Offering of Common Stock
09 August 2016 - 6:33AM
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an
offering, subject to market and other conditions, of 7,500,000
shares of its common stock in an underwritten public offering.
BioMarin has also granted the underwriters a 30-day option to
purchase an additional 750,000 shares of common stock. BioMarin
intends to use the net proceeds from the offering for general
corporate purposes, including clinical trials of its product
candidates and the expansion of its manufacturing capacity,
particularly with respect to its manufacturing capability for its
gene therapy program.
Goldman, Sachs & Co. and BofA Merrill Lynch are acting as
joint book-running managers for the offering.
The offering of the shares described above has been registered
under the Securities Act of 1933, as amended. For additional
information relating to the offering, BioMarin refers you to its
Registration Statement on Form S-3, which BioMarin filed with the
Securities and Exchange Commission (the “SEC”) on August 8, 2016
and which became immediately effective on the same date. A
preliminary prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and will be
available on the SEC's website at http://www.sec.gov. Copies
of the preliminary prospectus supplement and the accompanying
prospectus relating to the offering may also be obtained from
Goldman, Sachs & Co., Attention: Prospectus Department, 200
West Street, New York, NY 10282, by phone at (866) 471-2526 or by
email at prospectus-ny@ny.email.gs.com; and BofA Merrill Lynch,
NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC
28255-0001, Attn: Prospectus Department, or by email at
dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy the shares or any other securities,
and will not constitute an offer, solicitation or sale in any state
or jurisdiction in which such an offer, solicitation or sale would
be unlawful. The offering and sale of the shares will be made
pursuant to the effective shelf registration statement and only by
means of the prospectus supplement and the accompanying
prospectus.
About BioMarin
BioMarin develops and commercializes innovative
biopharmaceuticals for serious diseases and medical conditions.
BioMarin’s product portfolio consists of five approved products and
multiple clinical and pre-clinical product candidates.
Forward-Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995 including, without limitation, statements related to the
anticipated public offering of shares and statements regarding
BioMarin's intentions regarding the use of proceeds from the
offering. These forward-looking statements are based on the current
expectations of the management of BioMarin as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause actual
results of BioMarin to be materially different from those reflected
in the forward-looking statements. Important factors that could
cause actual results to differ materially from those indicated by
such forward-looking statements include, among others, market
risks. These and other risks are discussed in BioMarin's filings
with the SEC, including, without limitation, BioMarin's 2015 Annual
Report on Form 10-K, filed on February 29, 2016, and BioMarin's
periodic reports on Form 10-Q and Form 8-K, as well as the risks
identified in the registration statement and the preliminary
prospectus supplement relating to the offering. Given these
uncertainties, you should not place undue reliance on
forward-looking statements, which speak only as of the date hereof.
BioMarin is under no obligation, and expressly disclaims any
obligation to update or alter any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Contacts:
Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
Media
Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Apr 2024 to May 2024
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From May 2023 to May 2024